Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by thrombocytopenia, and T cell immune dysfunction plays an important role in the formation of ITP. As a thrombopoietin receptor agonist (TPO- RA), eltrombopag can not only directly stimulate megakaryocytes to produce platelets, but also play an immunomodulatory role by inducing regulatory T cell generation and reducing proinflammatory factors. As a second-line treatment drug for adult ITP, eltrombopag is increasingly widely used in clinical practice. This review summarized the latest research progress on the mechanism of action, efficacy, safety, and how to reduce the dosage of eltrombopag in ITP.
题目: 艾曲泊帕治疗成人原发免疫性血小板减少症的最新研究进展.
摘要: 原发免疫性血小板减少症（ITP）是一种以血小板减少为特征的自身免疫性疾病，T细胞免疫失调在ITP的形成过程中发挥了重要作用。艾曲泊帕是一种血小板生成素受体激动剂，除直接刺激巨核细胞生成血小板以外，还可通过诱导调节T细胞生成、降低促炎因子发挥免疫调节作用。艾曲泊帕作为成人ITP的二线治疗药物，在临床上的应用日益广泛。本文对艾曲泊帕在ITP中的作用机制、疗效、安全性及如何减量等最新研究进展作一综述。 .
Keywords: primary immune thrombocytopenia; immune abnormalities; eltrombopag; thrombosis; bone marrow fibrosis.